PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Krisztián Homicskó(University Hospital of Lausanne), Rolf A. Stahel(International Breast Cancer Study Group), Stephen P. Finn(Trinity College), Sylvie Rusakiewicz(Inserm), George Coukos(Ludwig Cancer Research), David Gilligan(University of Cambridge), Panagiota Zygoura(Frontier Science Foundation-Hellas), Ekaterina Fortis(Centre Hospitalier Universitaire Vaudois), James Spicer(King's College London), Alessandra Curioni‐Fontecedro(University of Fribourg), Nesa Marti(University of Bern), Sanjay Popat(Royal Marsden NHS Foundation Trust), Roswitha Kammler(International Breast Cancer Study Group), Solange Peters(University Hospital of Lausanne), Nicholas Shakarishvili(Centre Hospitalier Universitaire Vaudois), Urania Dafni(Frontier Science Foundation-Hellas), Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), Amy Roy(Plymouth Hospital), Anthony Pope(Clatterbridge Cancer Centre NHS Foundation Trust), Stéphanie Tissot(Centre Hospitalier Universitaire Vaudois), Mary O’Brien(Royal Marsden NHS Foundation Trust), P.M. Fisher(Weston Park Cancer Centre), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 14
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k